This study is in progress, not accepting new patients
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Michelle Melisko
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Michelle Melisko
Dr. Michelle E. Melisko is a cancer specialist with expertise in breast cancer treatment and research. She is interested in testing new chemotherapy combinations, biological therapies and immunotherapies for breast cancer, with a particular focus on treatment of cancer that has spread to the brain.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT02437318
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated